EcoDrugPlus

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSSVLG00005017231
Gene Symbol: CCR4
1 Cross references
254 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSSVLG00005023362
Gene Symbol: CCR5
1 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSSVLG00005023481
Gene Symbol: CCR9
1 Cross references
262 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSSVLG00005015148
Gene Symbol: CXCL8
1 Cross references
183 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSSVLG00005010741
Gene Symbol: CXCR1
1 Cross references
158 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSSVLG00005010719
Gene Symbol: CXCR2
1 Cross references
237 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSVLG00005002352
Gene Symbol: CXCR4
1 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSSVLG00005014470
Gene Symbol: CFTR
1 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSSVLG00005019922
Gene Symbol: DNMT1
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSVLG00005002957
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSSVLG00005022880
Gene Symbol: TOP2B
1 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSSVLG00005025264
Gene Symbol: EML4
1 Cross references
209 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).